Replies to post #438356 on NorthWest Biotherapeutics Inc (NWBO)

[ATLnsider]

Yes, that is what I believe.

But, I believe the analogy should be “2 grand slams”, because of the magnitude of the advancement DCVax-L will provide in treating ndGBM and rGBM patients (in terms of a significant increase in overall survival (OS) and significantly increasing the percentage of patients who are effectively cured (5+ years of complete remission) (DCVax-L alone will effectively cure upwards of 30% to 35% percent of DCVax-L treated patients) (probably an even higher percentage if you include future patients who will be treated with DCVax-L combined with Keytruda, and will also be effectively cured).

[newman2021]

yep, very interesting isn't it. If you assign a 14month mOS for rGBM from DcVaxL trial and compare it with the ECs that fall in line with an mOS of 7 months, of course a 100% improvement which is a second home run to Pazdur, imo. Recall 2018 JTM paper showed an 23months mOS blended that included the crossover or rGBM patients. Bingo!!